Straven Co

A Straven Institute article · 2 min read · 2026

AIDA not revived: no comprehensive federal AI statute contemplated

More from the Institute: The current body of work

Headline: AI buyers in Canada no longer shielded by lack of federal regulation; judgment must substitute for legislation.

What is happening: Straven & Co has found that the development of an AI validation firm in healthcare, where a confident but wrong answer can cost a life, serves buyers of AI, never builders of it, across healthcare and other regulated industries. This protection exists to guard clients against buying technology that does not do what was promised, deploying systems their governance cannot defend when regulators or courts ask questions, and from the quiet liability that now follows organisations held accountable for what their AI does and says.

Why it demands action now: The absence of a comprehensive federal AI statute in Canada means that buyers must ensure they are well-informed about AI capabilities before committing to an investment. This is particularly crucial for healthcare, insurance, and financial services executives, who need to balance the benefits of AI with its potential risks and liabilities.

The waiting-for-rules excuse is gone; judgment must substitute for regulation — Straven’s opening argument in Canada.

Straven & Co has found that it is crucial for organisations in regulated sectors to be aware of their exposure when buying or deploying AI. The absence of a comprehensive federal AI statute means buyers must take matters into their own hands and exercise independent judgment before making an investment decision.

How Straven helps: Straven & Co examines AI decisions before they are acted on by delivering plain verdicts based on real operations, people, governance obligations, and legal exposure. This ensures that buyers of AI are well-informed about the capabilities of a proposed solution and can make informed decisions about whether to proceed or not.

Straven & Co delivers independent validation against this situation for healthcare, insurance, and financial services organisations in Canada and the UK, providing them with the necessary guidance on how to assess an AI capability.